Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics Inc (PSTV)
NASDAQ:PSTV
PSTV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $2.67
Previous CloseN/A
Volume69.06K
Average Volume (3M)31.65M
Market Cap
$17.91M
Enterprise Value$10.08M
Total Cash (Recent Filing)$5.26M
Total Debt (Recent Filing)$14.20M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Apr 17, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares Outstanding11,785,078
10 Day Avg. Volume44,532,686
30 Day Avg. Volume31,646,796
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.79
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.11
Enterprise Value/Ebitda-0.85
Forecast
1Y Price Target
$7.25Price Target Upside525.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPlus Therapeutics is progressing well in its drug development with key milestones and data points expected in 2025.
Grant FundingThe company has received substantial grants, including $18 million from the Cancer Prevention and Research Institute of Texas and $3 million from the U.S. Department of Defense.
Regulatory DesignationRhenium (186Re) obisbemeda was granted orphan drug designation by the FDA for the treatment of breast cancer with LM.
Bears Say
Capital RaisesFuture capital raises are now estimated to occur at significantly lower share prices than previously anticipated.
Stock PerformanceStock weakness following the data presentation comes from an overreaction to a reported dose-limiting toxicity (hemiplegia).
Stock Price TargetThe price target has been decreased to $10 from $32 due to a dilutive effect from lower prices of future capital raises.
---
Ownership Overview
12.45% Insiders
1.53% Mutual Funds
9.51% Other Institutional Investors
75.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PSTV FAQ
What was Plus Therapeutics Inc’s price range in the past 12 months?
Plus Therapeutics Inc lowest stock price was $0.24 and its highest was $2.67 in the past 12 months.
What is Plus Therapeutics Inc’s market cap?
Plus Therapeutics Inc’s market cap is $17.91M.
When is Plus Therapeutics Inc’s upcoming earnings report date?
Plus Therapeutics Inc’s upcoming earnings report date is Apr 17, 2025 which is in 18 days.
How were Plus Therapeutics Inc’s earnings last quarter?
Plus Therapeutics Inc released its earnings results on Mar 27, 2025. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.497 by -$0.273.
Is Plus Therapeutics Inc overvalued?
According to Wall Street analysts Plus Therapeutics Inc’s price is currently Undervalued.
Does Plus Therapeutics Inc pay dividends?
Plus Therapeutics Inc does not currently pay dividends.
What is Plus Therapeutics Inc’s EPS estimate?
Plus Therapeutics Inc’s EPS estimate is -0.1.
How many shares outstanding does Plus Therapeutics Inc have?
Plus Therapeutics Inc has 11,785,078 shares outstanding.
What happened to Plus Therapeutics Inc’s price movement after its last earnings report?
Plus Therapeutics Inc reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.497. Following the earnings report the stock price went down -23.684%.
Which hedge fund is a major shareholder of Plus Therapeutics Inc?
Currently, no hedge funds are holding shares in PSTV
---
Company Description
Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
---
PSTV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of promising clinical trial results, successful financing, and strategic acquisitions that position Plus Therapeutics for future growth. However, these positives were offset by an increase in operating loss and a decline in cash reserves. The overall sentiment leans towards optimism due to strong forward-looking developments.Read More>---
PSTV Stock 12 Month Forecast
Average Price Target
$7.25
▲(525.00% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Adaptimmune Therapeutics
―
Cellectar Biosciences
―
Anavex Life Sciences
―
Cyclerion Therapeutics
―
Best Analysts Covering PSTV
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-25.99%
reiterated a buy rating 5 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -25.99% per trade.
---